End Stage Renal Disease (ESRD) Drug Global Market Report 2024

The end stage renal disease (esrd) drug market size has grown rapidly in recent years. It will grow from $116.32 billion in 2023 to $132.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%. The growth observed in the historical period can be attributed to several factors, including the increasing incidence of end-stage renal disease (ESRD), a growing aging population, improved access to healthcare services, government initiatives and policies supporting renal health, and an increasing adoption of renal replacement therapies. These factors collectively contributed to the expansion of the market for drugs and treatments related to end-stage renal disease during the historic period.

The end stage renal disease (esrd) drug market size is expected to see rapid growth in the next few years. It will grow to $232.13 billion in 2028 at a compound annual growth rate (CAGR) of 15.0%. The anticipated growth in the forecast period can be attributed to factors such as the emergence of new therapies and drug innovations, a continuous increase in healthcare expenditure, a rising global burden of chronic kidney diseases, the adoption of personalized medicine approaches, and regulatory support leading to expedited approvals. Major trends expected in this period include the increasing incidence of end-stage renal disease, advancements in treatment modalities, a growing emphasis on precision medicine, the development of combination therapies, and increased technological integration in healthcare practices. These trends collectively contribute to the positive outlook for the market for drugs and treatments related to end-stage renal disease in the forecast period.

The anticipated rise in obesity and diabetes cases is projected to be a significant driving force behind the growth of the end-stage renal disease (ESRD) drug market. Obesity, characterized by an abnormal or excessive accumulation of body fat, and diabetes, a chronic condition affecting insulin production or utilization, contribute to renal diseases. Managing fluid and electrolyte levels, blood pressure, and waste elimination through treatments such as dialysis can enhance overall health, potentially leading to weight reduction and improved blood sugar control. As reported by World Obesity in March 2022, the projected increase in obese individuals is estimated to reach 892 million by 2025 and escalate to 1,025 million by 2030. Additionally, the International Diabetes Federation (IDF) highlighted in September 2021 that approximately 537 million individuals aged 20 to 79 were living with diabetes in 2021, with projections indicating an increase to 643 million by 2030 and 783 million by 2045. Hence, the mounting cases of obesity and diabetes are poised to drive the demand for end-stage renal disease (ESRD) drugs.

The escalating prevalence of hypertension is another factor expected to propel the expansion of the end-stage renal disease (ESRD) drug market. Hypertension, characterized by consistently high blood pressure against artery walls, significantly impacts renal health. ESRD drugs play a crucial role in treating hypertension by regulating blood pressure, reducing cardiovascular risk, slowing disease progression, and enhancing fluid balance and quality of life. For example, according to the Centers for Disease Control and Prevention (CDC) in July 2023, hypertension accounted for 691,095 fatalities in the US in 2021. Consequently, the increasing prevalence of hypertension serves as a driving force behind the growth of the end-stage renal disease (ESRD) drug market.

Innovative product development emerges as a prominent trend shaping the end-stage renal disease (ESRD) drug market landscape. Leading companies within this sector are prioritizing the development of innovative solutions to bolster their market positions. A notable instance occurred in April 2022 when GlaxoSmithKline Plc, a UK-based pharmaceutical and biotechnology firm, announced the acceptance of the New Drug Application (NDA) for daprodustat by the US Food and Drug Administration (FDA). Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is aimed at potentially treating chronic kidney disease anaemia (CKD). This product is founded on groundbreaking science that elucidated cellular oxygen sensing and adaptation, marking a milestone in novel therapeutic approaches within the ESRD drug market.

Prominent companies in the end-stage renal disease (ESRD) drug market are strategically focusing on securing product approvals, exemplified by Jardiance, to augment their market revenues. Jardiance, featuring empagliflozin, is tailored to aid individuals diagnosed with type 2 diabetes and reduce the risk of cardiovascular complications in those with type 2 diabetes experiencing heart failure or cardiovascular disease. A significant development occurred in September 2023 when Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical company, obtained FDA approval for Jardiance. This drug has received approval for various indications, including reducing the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease prone to progression. Additionally, it aims to diminish the risk of sustained decline in estimated glomerular filtration rate (eGFR) in adults suffering from heart failure. Notably, Jardiance operates as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with contraindications for patients with type 1 diabetes and those exhibiting an eGFR lower than 20 ml/min/1.73 m.

In November 2021, Vifor Pharma, a Switzerland-based pharmaceutical company, acquired Sanifit Therapeutics S.A. for an undisclosed sum. This strategic acquisition served to broaden Vifor Pharma's portfolio by integrating cutting-edge assets. Sanifit Therapeutics S.A., headquartered in Spain, operates as a clinical-stage cardio-renal biopharmaceutical company specializing in developing therapies catering to individuals affected by end-stage kidney diseases. This acquisition marks a strategic expansion for Vifor Pharma, enhancing its expertise and offerings in addressing critical needs within the realm of end-stage renal diseases.

Major companies operating in the end stage renal disease (esrd) drug market report are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Cantel Medical Corp., Nikkiso Co. Ltd., Abbott Laboratories, Alere Inc., Siemens Healthcare AG, Roche Diagnostics Corporation, Beckman Coulter Inc., Becton Dickinson And Co., Thermo Fisher Scientific Inc., BioMerieux SA, Bio-Rad Laboratories, Randox Laboratories, Enzo Biochem Inc., Merck Co. & KGaA, QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH.

North America was the largest region in the end stage renal disease (ESRD) drug market in 2023. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the end stage renal disease (esrd) drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main categories of End Stage Renal Disease (ESRD) drugs include calcimimetics, vitamin D, sterols, potassium binders, calcium-based phosphate binders, and others. Calcimimetics are used to reduce parathyroid hormone (PTH) levels in kidney disease stage 5D, with their application dependent on serum calcium and phosphorus levels. Various indications for these drugs include ESRD-induced hyperparathyroidism, hyperphosphatemia, and hyperkalemia. End Stage Renal Disease drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, catering to usage in hospitals, homecare settings, specialty clinics, and other end-user environments.

The end stage renal disease (ESRD) drug market research report is one of a series of new reports that provides end stage renal disease (ESRD) drug market statistics, including end stage renal disease (ESRD) drug industry global market size, regional shares, competitors with an end stage renal disease (ESRD) drug market share, detailed end stage renal disease (ESRD) drug market segments, market trends and opportunities, and any further data you may need to thrive in the end stage renal disease (ESRD) drug industry. This end stage renal disease (ESRD) drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.